Twin Tree Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Twin Tree Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.19M	Sell	21,100 -33,800	-62%	-$1.97M	0.03%	666
2025 Q4	$3.26M	Buy	54,900 +30,100	+121%	+$1.64M	0.03%	663
2025 Q3	$1.34M	Buy	24,800 +18,200	+276%	+$1.04M	0.01%	1134
2025 Q2	$363K	Buy	+6,600	New	+$389K	﹤0.01%	1468
2024 Q1	–	Sell	-7,200	Closed	-$694K	–	1284
2023 Q4	$694K	Buy	+7,200	New	+$637K	﹤0.01%	1166
2023 Q2	–	Sell	-18,100	Closed	-$1.76M	–	1259
2023 Q1	$1.76M	Sell	18,100 -11,200	-38%	-$1.16M	﹤0.01%	925
2022 Q4	$3.03M	Buy	+29,300	New	+$2.75M	0.01%	848
2022 Q2	–	Sell	-5,400	Closed	-$416K	–	1502
2022 Q1	$416K	Buy	+5,400	New	+$452K	﹤0.01%	1402
2021 Q2	–	Sell	-4,300	Closed	-$325K	–	1341
2021 Q1	$325K	Buy	+4,300	New	+$351K	﹤0.01%	1103
2020 Q4	–	Sell	-8,800	Closed	-$670K	–	1276
2020 Q3	$670K	Buy	+8,800	New	+$890K	﹤0.01%	939

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Tree Management's BMRN Position: Q3 2025 in Review

Twin Tree Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 10,703 shares — an estimated $612K sold.

Twin Tree Management first reported a position in BMRN in Q1 2018 and held it in 18 quarters. The position peaked at $6.94M in Q4 2022. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Twin Tree Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Twin Tree Management sold 10,703 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $612K.
Twin Tree Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 18 quarters.
Twin Tree Management's BioMarin Pharmaceuticals position peaked at $6.94M in Q4 2022.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.